Pomerantz RJ - Search Results

1

Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vector.

Cordelier P, Calarota SA, Pomerantz RJ, Xiaoshan J, Strayer DS. Cordelier P, et al. Among authors: pomerantz rj. J Interferon Cytokine Res. 2003 Sep;23(9):477-88. doi: 10.1089/10799900360708605. J Interferon Cytokine Res. 2003. PMID: 14565857

2

Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.

BouHamdan M, Duan LX, Pomerantz RJ, Strayer DS. BouHamdan M, et al. Among authors: pomerantz rj. Gene Ther. 1999 Apr;6(4):660-6. doi: 10.1038/sj.gt.3300864. Gene Ther. 1999. PMID: 10476226

3

SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.

Jayan GC, Cordelier P, Patel C, BouHamdan M, Johnson RP, Lisziewicz J, Pomerantz RJ, Strayer DS. Jayan GC, et al. Among authors: pomerantz rj. Gene Ther. 2001 Jul;8(13):1033-42. doi: 10.1038/sj.gt.3301481. Gene Ther. 2001. PMID: 11438838

4

Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection.

Marusich EI, Parveen Z, Strayer D, Mukhtar M, Dornburg RC, Pomerantz RJ. Marusich EI, et al. Among authors: pomerantz rj. Virology. 2005 Feb 5;332(1):258-71. doi: 10.1016/j.virol.2004.11.012. Virology. 2005. PMID: 15661158 Free article.

5

Current status of gene therapy strategies to treat HIV/AIDS.

Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA. Strayer DS, et al. Among authors: pomerantz rj. Mol Ther. 2005 Jun;11(6):823-42. doi: 10.1016/j.ymthe.2005.01.020. Mol Ther. 2005. PMID: 15922953 Free article. Review.

6

Combination genetic therapy to inhibit HIV-1.

Strayer DS, Branco F, Landré J, BouHamdan M, Shaheen F, Pomerantz RJ. Strayer DS, et al. Among authors: pomerantz rj. Mol Ther. 2002 Jan;5(1):33-41. doi: 10.1006/mthe.2001.0513. Mol Ther. 2002. PMID: 11786043 Free article.

7

Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.

Goldstein H, Pettoello-Mantovani M, Anderson CM, Cordelier P, Pomerantz RJ, Strayer DS. Goldstein H, et al. Among authors: pomerantz rj. J Infect Dis. 2002 May 15;185(10):1425-30. doi: 10.1086/340210. Epub 2002 Apr 22. J Infect Dis. 2002. PMID: 11992277

8

Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.

Strayer DS, Pomerantz RJ, Yu M, Rosenzweig M, BouHamdan M, Yurasov S, Johnson RP, Goldstein H. Strayer DS, et al. Among authors: pomerantz rj. Gene Ther. 2000 May;7(10):886-95. doi: 10.1038/sj.gt.3301159. Gene Ther. 2000. PMID: 10845727

9

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.

Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS. Cordelier P, et al. Among authors: pomerantz rj. Gene Ther. 2004 Nov;11(22):1627-37. doi: 10.1038/sj.gt.3302329. Gene Ther. 2004. PMID: 15295615

10

A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line.

Zern MA, Ozaki I, Duan L, Pomerantz R, Liu SL, Strayer DS. Zern MA, et al. Gene Ther. 1999 Jan;6(1):114-20. doi: 10.1038/sj.gt.3300793. Gene Ther. 1999. PMID: 10341883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

244 results

Search Page